Edwards Lifesciences Corporation (FRA:EWL)

Market Cap	39.30B -3.7%
Revenue (ttm)	5.17B +11.5%
Net Income	914.30M -74.3%
EPS	1.56 -73.7%
Shares Out	n/a
PE Ratio	42.98
Forward PE	26.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60
Average Volume	96
Open	66.91
Previous Close	66.96
Day's Range	66.72 - 67.63
52-Week Range	59.49 - 74.98
Beta	n/a
RSI	49.58
Earnings Date	Feb 10, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EWL

Financial Performance

In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.

Financial numbers in USD